On July 5, 2017, Daiichi Sankyo Company announced that it has decided to discontinue the development of CHS-0214, an investigational biosimilar to Amgen’s Enbrel® (etanercept), in Japan.  Daiichi had been co-developing CHS-0214 with Coherus BioSciences, who still holds rights to CHS-0214 outside of Japan.  According to the announcement, CHS-0214 had met its primary endpoint of equivalence in the treatment of rheumatoid arthritis, but Daiichi decided to discontinue development due to the lack of a feasible commercial manufacturing process for CHS-0214.